Americans spend $43 billion annually on cancer screenings, study reveals

Americans spend $43 billion annually on cancer screenings, study reveals

Study Highlights Costs and Implications of Cancer Screenings

Cancer remains a leading cause of death in the United States, and a recent study has revealed that Americans spend over $40 billion annually on cancer screenings. The study, conducted by the American College of Physicians, examined data from 2021 for five common cancers: breast, cervical, colorectal, lung, and prostate.

Methodology and findings

Published in the Annals of Internal Medicine, the study utilized healthcare survey and cost resource data from the National Institutes of Health to estimate the annual cost of initial cancer screenings, excluding follow-up costs. By multiplying the number of screenings by the typical insurance coverage cost per screen, researchers estimated the total expenditure to be $43 billion per year.

Colorectal cancer screenings accounted for the highest cost, comprising 64% of the total expenditure. Private insurance covered 88.3% of these costs, followed by Medicare at 8.5%, and Medicaid and other programs at 3.2%.

“About 88.3% of costs were attributable to private insurance, 8.5% to Medicare, and 3.2% to Medicaid and other programmes,” said a release from the college. 

Policy implications

The American College of Physicians hopes that these findings will inform policy changes to ensure equal access to cancer screenings and treatments. “Cancer screenings increase detection of earlier-stage disease, which may result in decreased treatment costs, decreased financial hardship, and improved quality of life,” the college stated in a release.

However, the $43 billion estimate may be conservative, as it does not account for additional testing, screening of ineligible patients, overdiagnosis, and overtreatment. “Data suggests that screening of ineligible patients is particularly common, especially among elderly people,” the college noted in an accompanying editorial.

The study underscores the significant financial burden of cancer screenings in the U.S. while highlighting the importance of early detection in reducing mortality rates and treatment costs. The findings aim to drive policy changes that promote equitable access to these essential health services.

Exit mobile version